Our Impact

Universities don’t make drugs. With the help of scaling partners, IMA projects are advancing beyond the walls of Stanford toward solutions for patients.

Success Stories

With support from the IMA, projects that started at Stanford have made their way beyond our walls. IMA-supported products have been licensed to new spinout companies, licensed to biotech and pharmaceutical companies, and advanced to nonprofit-backed clinical trials.

Decorative image

Entrepreneur-in-residence launches cancer biotech

Decorative image

New company tricks cancer cells into self-destructing

Decorative image

Nobel laureate launches startup for new cancer immunotherapy

Decorative image

New hope from old drugs for cystic fibrosis: startup explores combination therapy

Decorative image

New depression biomarker enables clinical trial in precision therapies

Decorative image

COVID-19 study sparks new company exploring first-in-class medicines for rare pulmonary diseases

New stable and affordable COVID vaccine could revolutionize global vaccine distribution

New drug candidate could make existing cancer immunotherapies more effective

In the news